Acobiom’s business model is based on two main activities:
(1) developing and commercializing diagnostics and companion diagnostics (CDx), notably for precision medicine applications;
(2) providing services in the fields of genomics, pharmacogenomics, and transcriptomics, for research purposes and clinical trials.
To reach its objectives, the company has developed and continually refined a technology platform associating high-throughput technologies (sequencing, NGS, qRT-PCR), and proprietary bioinformatic and biostatistical tools.
Acobiom decided to invest the precision medicine field in developing innovative diagnostics to adapt treatment to patients, especially in oncology and neurodegenerative diseases.
To know more about Acobiom’s core business, please download the following presentation: Corporate presentation.
To obtain more information concerning the expertise of Acobiom in Biomarker discovery and Diagnostic development, in its technology know-how in genomics, pharmacogenomics, transcriptomics, bioinformatics, please download the document: « ACOBIOM Expertises »
For its services business, Acobiom has been granted a Research Tax Relief (« Agrément Crédit Impôt Recherche ») by the French Ministry of Research and Technology, enabling industry clients to apply the company’s services to their research tax credits.
If you require any additional information concerning our company, please contact our corporate department: +33(0)467 419 748.